Search Main Menu Main Content
  • Change contrast :
Haute Autorité de Santé
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

  • No element in selection

  • Contact

1 result

  • Active substance : rifampicine
  • Active substance : acide clavulanique
  • Active substance : amikacine
  • Active substance : ceftriaxone
Filter
Topic
  • Economics and public health (1)
  • Plus ...
    • Organisation of care (1)
  • Diseases and conditions (1)
  • Plus ...
    • Infectious diseases (1)
    • Plus ...
      • Bacterial infections (1)
  • Quality of care and patient safety (1)
  • Plus ...
    • Quality of care and patient safety (1)
Content type
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Manufacturer
  • alter (1)
Language
  • Français (1)
Active substance
  • acide clavulanique (1)
  • acide fusidique (1)
  • acide nalidixique (1)
  • amikacine (1)
  • amoxicilline (1)
  • ceftazidime (1)
  • ceftriaxone (1)
  • ciprofloxacine (1)
  • clindamycine (1)
  • gentamicine (1)
  • rifampicine (1)
  • tazobactam (1)
  • tobramycine (1)
  • vancomycine (1)

Practice guidelines and other guides - 1 result

  • Antibiotic therapy and prevention of bacterial resistance in healthcare organisations

    Practice guidelines - Posted on 29/5/2008
    Download abstract
    Add to my selection
Haute Autorité de Santé
Advancing quality in the fields of health and social care services

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • fr Français
  • en English
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
DFrSkDMkEHTD9RYn